Loading...
XNAS
BYSI
Market cap61mUSD
Jul 09, Last price  
1.49USD
1D
-10.78%
1Q
-14.37%
IPO
-92.26%
Name

Beyondspring Inc

Chart & Performance

D1W1MN
XNAS:BYSI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.15%
Rev. gr., 5y
0.00%
Revenues
0k
000000180,0001,351,0001,351,000000
Net income
-8m
L-28.15%
-3,013,000-7,970,000-12,010,000-91,763,000-54,869,000-38,085,000-60,973,000-64,179,000-33,279,000-21,026,000-11,123,000-7,992,000
CFO
-20m
L+21.77%
-1,146,000-6,570,000-13,698,000-28,796,000-39,955,000-48,162,000-43,745,000-47,242,000-28,151,000-16,474,000-16,443,000-20,023,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
URL
https://www.beyondspringpharma.com/en/
IPO date
Mar 09, 2017
Employees
73
Domiciled in
US
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT